China expands its manufacturing role for biopharma’s new drugs
A growing number of FDA-approved innovators and biosimilars are being manufactured at China-based facilities as biopharma takes interest in the country’s biologic API manufacturing industry. However, this is being met with pushback from US policymakers amid efforts to onshore pharmaceutical manufacturing.
